Tirilazad
Jump to navigation
Jump to search
Clinical data | |
---|---|
Other names | (8S,10S,13S,14S,16R,17S)-17-[2-[4-(2,6-dipyrrolidin-1-ylpyrimidin-4-yl)piperazin-1-yl]acetyl]-10,13,16-trimethyl-6,7,8,12,14,15,16,17-octahydrocyclopenta[a]phenanthren-3-one |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C38H52N6O2 |
Molar mass | 624.874 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Tirilazad is a drug that has been proposed to treat acute ischaemic stroke. When tested on animal models, tirilazad protects brain tissue, and reduces brain damage. However, the drug fails to treat, and even worsens a stroke when studied on a human being.[1]
References
- ^ Bath PM, Iddenden R, Bath FJ, Orgogozo JM, et al. (Tirilazad International Steering Committee) (2001). "Tirilazad for acute ischaemic stroke". The Cochrane Database of Systematic Reviews (4): CD002087. doi:10.1002/14651858.CD002087. PMID 11687138.
Categories:
- Articles with short description
- Short description matches Wikidata
- Articles with changed CASNo identifier
- Articles with changed EBI identifier
- Chemical pages without DrugBank identifier
- Drugs with no legal status
- Drugboxes which contain changes to verified fields
- Piperazines
- Pregnanes
- Aminopyrimidines
- 1-Pyrrolidinyl compounds
- All stub articles
- Nervous system drug stubs